Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588229 | 1.00 | ACHE (0.56) | ACHEALDH1A1MAPTSIGMAR1HRH3 | |
| SCHEMBL3355426 | 0.89 | ALDH1A1 (0.63) | ACHEALDH1A1HRH3KDM4EHRH2 | |
| SCHEMBL13291354 | 0.89 | ALDH1A1 (0.63) | ACHEALDH1A1HRH3KDM4EHRH2 | |
| SCHEMBL1357166 | 0.89 | ALDH1A1 (0.63) | ACHEALDH1A1HRH3KDM4EHRH2 | |
| SCHEMBL18779478 | 0.87 | ALDH1A1 (0.71) | ALDH1A1MAPTHRH3KDM4EHRH2 | |
| SCHEMBL30596558 | 0.87 | ALDH1A1 (0.71) | ALDH1A1MAPTHRH3KDM4EHRH2 | |
| Ammonia Solution, Strong SCHEMBL28922498 | 0.87 | ALDH1A1 (0.61) | ACHEALDH1A1HRH3KDM4EHRH2 | |
| SCHEMBL6694425 | 0.87 | ALDH1A1 (0.71) | ALDH1A1MAPTHRH3KDM4EHRH2 | |
| SCHEMBL12424244 | 0.87 | ACHE (0.61) | ACHEALDH1A1MAPTSIGMAR1HRH3 | |
| SCHEMBL14432562 | 0.85 | ALDH1A1 (0.69) | ALDH1A1MAPTHRH3KDM4EHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| EP-3638672-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| CN-110753692-A | Chemical compounds as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2019049061-A1 | 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-14 | — | — | WO | disclosed |
| WO-2018229629-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | WO | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | HPGDS, PTGS1, PTGIS | ACHE 2326/4885ALDH1A1 918/4885MAPT 4769/4885 |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | HPGDS, PTGS1, PTGIS | ACHE 2349/4885ALDH1A1 889/4885MAPT 4760/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | ACHE 873/4885ALDH1A1 1153/4885MAPT 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.